Lachesis Biosciences

@LachesisBiosci1

We are a clinical stage company developing pro-cognitive pharmaceutical products for neurodegenerative disease, also known as dementia.

Victoria, Australia
Vrijeme pridruživanja: prosinac 2019.

Tweetovi

Blokirali ste korisnika/cu @LachesisBiosci1

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @LachesisBiosci1

  1. 4. velj

    Lachesis: Expedited Path to Market with a significantly De-risked Asset

    Poništi
  2. 3. velj

    Alzheimer's Disease Genetics Fact Sheet

    Poništi
  3. 2. velj

    Sales of Exelon® for Alzheimer's Disease were limited by some nasty side effects - Lachesis has developed a nasal spray for Exelon® that eliminates those side effects. 's

    Poništi
  4. 2. velj
    Poništi
  5. 30. sij

    Lachesis is developing a rivastigmine nasal spray for the treatment of mild to severe Alzheimer's and mild to moderate Parkinson's disease - significantly derisked and expedited approach 's ’s

    Poništi
  6. 28. sij

    Next steps for Lachesis: running a pivotal efficacy and safety study of LBIO-R32 's

    Poništi
  7. 28. sij

    A Brain Scientist Who Studies Alzheimer's Explains How She Stays Mentally Fit 's

    Poništi
  8. 27. sij

    Alzheimer's disease: An eye test could provide early warning 's

    Poništi
  9. 25. sij

    An uncommon form of dementia hits at a younger age. Drug makers are searching for a treatment

    Poništi
  10. 25. sij
    Poništi
  11. 24. sij

    Possible Missing Link in Alzheimer's Pathology Identified

    Poništi
  12. 23. sij

    Alzheimer's Disease Genetics Fact Sheet

    Poništi
  13. 23. sij

    Alzheimer's Disease Linked to Exposure to Aluminum

    Poništi
  14. 23. sij

    Lachesis is developing a rivastigmine nasal spray for the treatment of mild to severe Alzheimer's and mild to moderate Parkinson's disease - significantly derisked and expedited approach 's ’s

    Poništi
  15. 22. sij
    Poništi
  16. 21. sij

    Lachesis: Expedited Path to Market with a significantly De-risked Asset

    Poništi
  17. 21. sij

    Sales of Exelon® for Alzheimer's Disease were limited by some nasty side effects - Lachesis has developed a nasal spray for Exelon® that eliminates those side effects. 's

    Poništi
  18. 20. sij

    In the world of pharmaceutical product development, an effective drug to treat Alzheimer's disease (AD) is the Holy Grail. 's

    Poništi
  19. 18. sij

    Lachesis: Expedited Path to Market with a significantly De-risked Asset

    Poništi
  20. 17. sij

    Nasal sprays for drug delivery, are a common alternative to oral or intravenous dosing of pharmaceutical products.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·